Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery
Key Takeaways
- Botox (onabotulinumtoxinA) currently has 12 FDA-approved indications across both therapeutic and cosmetic uses.
- The FDA boxed warning highlights the risk of toxin spread, which can cause serious or life-threatening symptoms.
- On-label use at approved doses with a qualified provider offers the lowest-risk treatment path.
- Off-label Botox use is common and legal, but it calls for added provider expertise and clear informed consent.
- Patients who want safe, evidence-based Botox care can book a consultation with Mirror Plastic Surgery for a detailed assessment and documented treatment plan.
Botox FDA Status and Regulatory Background
Botox is the brand name for onabotulinumtoxinA, a purified neurotoxin protein that temporarily blocks nerve signals to targeted muscles or glands. Botox first received FDA approval in 1989 for the treatment of eye conditions including strabismus and blepharospasm. Since that initial clearance, the FDA has granted additional approvals across both therapeutic and cosmetic categories. AbbVie states that Botox now carries multiple approved indications and more than 30 years of post-approval experience. As of April 2026, the FDA confirms that Botox remains one of only six FDA-approved cosmetic botulinum toxin products available in the United States, alongside Daxxify, Dysport, Jeuveau, Letybo, and Xeomin.
Current FDA-Approved Uses for Botox
The table below lists every current FDA-approved indication for onabotulinumtoxinA, organized by category and approval year. All data come from the official prescribing information and AbbVie’s published materials.
| Indication | Category | Year Approved | Source |
|---|---|---|---|
| Strabismus and blepharospasm (patients ≥12 years) | Therapeutic | 1989 | ASPS |
| Cervical dystonia (abnormal head position and neck pain) | Therapeutic | 2000 | AbbVie |
| Glabellar lines, moderate to severe (cosmetic) | Cosmetic | 2002 | Wikipedia / FDA record |
| Severe primary axillary hyperhidrosis | Therapeutic | 2004 | AbbVie |
| Chronic migraine prophylaxis (adults, ≥15 headache days/month) | Therapeutic | 2010 | Wikipedia / FDA record |
| Urinary incontinence, neurogenic detrusor overactivity (adults) | Therapeutic | 2011 | AbbVie |
| Overactive bladder, urge incontinence, urgency, frequency (adults) | Therapeutic | 2013 | AbbVie |
| Lateral canthal lines (crow’s feet), moderate to severe (cosmetic) | Cosmetic | 2013 | Botox Cosmetic HCP |
| Upper-limb spasticity (adults and pediatric patients ≥2 years) | Therapeutic | 2010 / expanded 2016 | AbbVie |
| Forehead lines, moderate to severe (cosmetic) | Cosmetic | 2017 | Botox Cosmetic HCP |
| Neurogenic detrusor overactivity, pediatric patients ≥5 years | Therapeutic | 2021 | AbbVie |
| Platysma bands, moderate to severe (cosmetic) | Cosmetic | 2023–2024 | Botox Cosmetic HCP |
Botox Cosmetic is the only neurotoxin FDA-approved for four distinct aesthetic indications, and it is the first product of its kind cleared for the treatment of platysma bands, the vertical cords connecting the neck and jaw.
FDA Approval for Forehead Lines
The FDA approved Botox Cosmetic for moderate to severe forehead lines associated with frontalis muscle activity in 2017. This approval applies to adult patients and focuses on dynamic lines created by movement rather than static lines present at rest. The prescribing information defines dosing parameters that aim for visible softening without altering brow position or upper-eyelid function. Realistic outcomes include a smoother forehead at rest and reduced line depth during expression.1 Complete removal of every line is not a typical clinical goal.1 Outcome quality depends heavily on the injector’s assessment of frontalis anatomy, brow position, and compensatory muscle activity before treatment.
Book a consultation with Ellie to receive a thorough anatomical assessment before any forehead treatment is planned.
Serious Risks Highlighted in the FDA Boxed Warning
The single most significant risk identified by the FDA is toxin spread beyond the injection site. The FDA boxed warning states that postmarketing reports document the effects of Botox spreading from the area of injection to produce symptoms consistent with systemic botulinum toxin effects, including generalized muscle weakness, difficulty swallowing (dysphagia), difficulty speaking (dysarthria), double vision (diplopia), drooping eyelids (ptosis), voice changes (dysphonia), urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection, swallowing and breathing difficulties can be life-threatening, and there have been reports of death. The boxed warning notes that the risk of spread is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly those with underlying conditions that predispose them to these effects. Cases of spread have been reported at doses comparable to those used for cervical dystonia and spasticity, and at lower doses in both unapproved and approved indications.
Additional serious adverse events documented in postmarketing surveillance include:
- Cardiovascular events including arrhythmia and myocardial infarction, some with fatal outcomes
- Death associated with dysphagia, pneumonia, and significant debility, or anaphylaxis
- Partial facial paralysis, eyelid drooping, crooked brows or smile, drooling, dry eyes, or excessive tearing
In the chronic migraine clinical trials, the most frequently reported adverse reactions included neck pain, headache, eyelid ptosis, muscular weakness, and facial paresis. The CDC notes that the cosmetic procedure is considered safe when a licensed provider correctly injects specific muscles with recommended amounts of an FDA-approved product, but the procedure is not risk-free. This risk profile sits against a long regulatory history, outlined below, which helps patients understand how Botox reached its current role in medicine and aesthetics.
Botox FDA Approval History Timeline (1989–2026)
| Year | Milestone | Category | Source |
|---|---|---|---|
| 1989 | First FDA approval for therapeutic eye indications (see above) | Therapeutic | ASPS |
| 2000 | Cervical dystonia approved | Therapeutic | AbbVie |
| 2002 | First cosmetic approval: glabellar lines (frown lines) | Cosmetic | Wikipedia / FDA record |
| 2004 | Severe primary axillary hyperhidrosis approved | Therapeutic | AbbVie |
| 2010 | Chronic migraine prophylaxis approved (October 15, 2010) | Therapeutic | Wikipedia / FDA record |
| 2011 | Urinary incontinence, neurogenic detrusor overactivity (adults) approved | Therapeutic | AbbVie |
| 2013 | Overactive bladder (adults) and lateral canthal lines (crow’s feet) approved | Both | AbbVie / Botox Cosmetic HCP |
| 2016 | Spasticity indication expanded to pediatric patients ≥2 years | Therapeutic | AbbVie |
| 2017 | Forehead lines approved as third cosmetic indication | Cosmetic | Botox Cosmetic HCP |
| 2021 | Neurogenic detrusor overactivity expanded to pediatric patients ≥5 years | Therapeutic | AbbVie |
| 2023–2024 | Platysma bands approved as fourth cosmetic indication | Cosmetic | Botox Cosmetic HCP |
On-Label and Off-Label Botox: What Patients Can Expect
FDA-approved use means the FDA has determined that a product is safe and effective for a specific use based on clinical studies and testing. Off-label use means a medication is being used in a different way than what was approved, based on research and physician expertise; such use is legal and legitimate.
Off-label use is common for many medications. Common off-label cosmetic applications of Botox include masseter reduction for jawline slimming, lip flips, and trapezius injections (often called “Traptox” or “Barbie Botox”). Masseter injection is technically off-label but is described by plastic surgeons as one of the most effective ways to slim the lower face and address jaw clenching. Other off-label therapeutic uses include jaw tension or TMJ-related symptoms, pelvic floor muscle dysfunction, and certain types of neuropathic pain.
Off-label does not mean experimental or unsafe. It usually means the provider is tailoring the treatment to the patient’s anatomy and goals using tools with an established track record. The critical safety variable is whether the provider uses an FDA-approved product at appropriate doses and documents the treatment accurately. Serious adverse reactions including excessive weakness, dysphagia, and aspiration pneumonia have been reported in patients who received Botox for unapproved uses, which highlights the importance of provider expertise for both on-label and off-label care.
Long-Term Botox Use and Maintenance Planning
Botox produces temporary effects. Duration varies by indication, injection site, dose, and individual metabolism, but most cosmetic results last about three to four months before retreatment makes sense.1 Consistent treatment intervals with the same provider create a cumulative record of dose, response, and anatomical changes over time. These data support safer, more precise future sessions.
Long-term use does not appear to cause permanent muscle damage at standard cosmetic doses.1 Repeated injections can gradually change muscle mass and resting tone, which shifts the aesthetic baseline.1 Patients who switch providers frequently lose the benefit of longitudinal documentation, which can lead to inconsistent dosing and less predictable outcomes. Maintaining a relationship with a single, records-keeping provider supports both safety and aesthetics.
Checking That Your Botox Is FDA-Approved and Properly Dosed
Patients can take concrete steps to confirm that their treatment meets FDA standards:
- Request lot number verification. Every vial of Botox carries a lot number traceable to AbbVie’s manufacturing records. A transparent provider will share this on request.
- Confirm the product name. The only FDA-approved cosmetic botulinum toxin products as of April 2026 are Botox, Daxxify, Dysport, Jeuveau, Letybo, and Xeomin. Any product outside this list is not FDA-approved for cosmetic use in the United States.
- Ask about dose documentation. Units injected per site should be recorded in your chart. This supports consistent retreatment and helps with complication management if needed.
- Inquire about the provider’s training. Injectors should be licensed healthcare professionals with documented training in facial anatomy and neuromodulator administration.
- Discuss your full medical history. Botox is contraindicated in the presence of infection at the proposed injection site and in patients who are hypersensitive to any botulinum toxin product or to any component of the formulation.
Book a consultation with Ellie to review your medical history, confirm product sourcing, and receive a documented, individualized treatment plan before any injection is performed.
Safety-First Botox Planning With an Expert Provider
Aesthetic treatments are real medical procedures and can have serious, life-altering, and life-threatening complications. A thorough pre-treatment anatomical assessment that evaluates muscle depth, brow position, skin laxity, and compensatory movement patterns forms the foundation of safe neuromodulator care. Individualized planning recognizes that standard dosing protocols are population averages, not one-size-fits-all prescriptions.
Transparent risk-benefit discussions before treatment help patients weigh the boxed warning against their specific health profile and aesthetic goals. Providers who spend adequate time on this conversation, document findings, and follow up after treatment are better positioned to detect early adverse events and respond appropriately. Patients should always talk to a trained provider to understand the risks and benefits for their individual situation.
Frequently Asked Questions
Is Botox safe for long-term use?
At standard cosmetic doses, Botox has been used continuously by millions of patients since its first cosmetic approval in 2002 without evidence of permanent systemic harm in healthy adults.1 Long-term use can gradually reduce the bulk of repeatedly treated muscles, which may alter the aesthetic baseline over time.1 Consistent provider records and periodic reassessment of dose and technique are reliable safeguards for patients who maintain ongoing treatment schedules.
What is the difference between Botox and other neuromodulators like Dysport or Daxxify?
Botox, Dysport, Xeomin, Jeuveau, Daxxify, and Letybo are all FDA-approved botulinum toxin type A products, but they differ in formulation, unit dosing, onset speed, and duration. Daxxify, for example, uses a peptide-based stabilizer that may extend duration of effect compared to traditional formulations. Unit doses are not interchangeable across brands, so a unit of Dysport is not equivalent to a unit of Botox. An experienced injector selects the most appropriate product based on the treatment area, patient history, and desired outcome rather than defaulting to a single brand.
Can Botox be used if I am pregnant or breastfeeding?
The FDA has not established the safety of Botox during pregnancy or breastfeeding. Most clinical guidelines recommend avoiding elective neuromodulator injections during these periods. Patients who are pregnant, planning to become pregnant, or breastfeeding should disclose this during consultation so the provider can defer treatment or discuss the risk profile in full.
How do I know if a Botox result is normal or a sign of a complication?
Mild redness, swelling, and tenderness at injection sites are expected and typically resolve within 24 to 48 hours.1 Eyelid or brow drooping that appears within the first two weeks may indicate unintended toxin spread to adjacent muscles and should be reported to the treating provider promptly. Symptoms such as difficulty swallowing, speaking, or breathing after any Botox injection, cosmetic or therapeutic, require immediate emergency medical attention, as these are consistent with the spread effects described in the FDA boxed warning.
How should I choose a Botox provider?
Patients should prioritize licensed healthcare professionals with documented training in facial anatomy and neuromodulator pharmacology. Ask whether the practice uses FDA-approved products, records lot numbers and doses in patient charts, and conducts a thorough pre-treatment assessment rather than a brief intake. Providers who take time to review your full medical history, explain the rationale for recommended doses, and offer follow-up care after treatment are better equipped to manage both routine outcomes and unexpected adverse events.
Summary: Making Evidence-Based Botox Choices
Botox carries 12 FDA-approved indications across therapeutic and cosmetic categories, a documented approval history stretching from 1989 through the 2023–2024 platysma-bands expansion, and a boxed warning that every patient deserves to understand before treatment. The regulatory record shows that on-label use at approved doses with a qualified provider represents the lowest-risk pathway. Off-label applications, while legal and often clinically sound, call for additional provider expertise and transparent informed consent.
For patients in the St. Petersburg and Tampa Bay area who want individualized neuromodulator care, Mirror Plastic Surgery’s concierge model offers up to an hour of pre-treatment assessment, full dose documentation, FDA-approved product sourcing, and follow-up support. This standard of care reflects the evidence-based approach that the current regulatory landscape supports.
Book a consultation with Ellie to begin with a thorough anatomical assessment and a transparent, individualized treatment plan grounded in the full FDA record.
Disclaimer: Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
